Posted by Michael Wonder on 23 Jan 2019
Vertex’s CF drug gets label extension as pricing row continues Vertex’s CF drug gets label extension as pricing row continues
23 January 2019 - While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in younger children.
The Commission has approved the drug for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. Previously, this indication was only approved for patients aged 6 and above.
Vertex has been trying to strike a long-term deal that would involve the NHS funding all of its CF drugs, including those that are yet to be approved.
